Hapoalim Securities Analyst Recommendations & Stock PicksView the latest stock recommendations issued by analysts at Hapoalim Securities. This page tracks publicly reported analyst upgrades and downgrades, buy/hold/sell ratings, and price target changes for publicly traded companies. All data is compiled from credible public sources and updated regularly to reflect new insights from Hapoalim Securities' equity research team. MarketBeat is not affiliated with or endorsed by Hapoalim Securities.Updated 5/24/2021 Brokerage RankingSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROITotal Ratings0 Last 12 MonthsBuy Ratings0 Last 12 MonthsSell Ratings0 Last 12 Months Country All Countries USA (NYSE & NASDAQ)USA (All Exchanges)CanadaUnited Kingdom Sector All Sectors AerospaceAuto/Tires/TrucksBasic MaterialsBusiness ServicesCommunication ServicesComputer and TechnologyConstructionConsumer CyclicalConsumer DefensiveConsumer DiscretionaryConsumer GoodsConsumer StaplesEnergyFinanceFinancial ServicesIndustrialsManufacturingMedicalMiscellaneousMulti-Sector ConglomeratesReal EstateRetail/WholesaleServicesTransportationUtilities Market Cap All MarketCaps Mega Cap (More Than $200B)Large Cap ($10B-$200B)Mid Cap ($2B-$10B)Small Cap ($300M-$2B)Micro Cap ($50M-$300M)Nano Cap (Under $50M) MarketRank™ evaluates a company based on dividend strength, earnings, valuation, analysts forecasts, and more.Available with a MarketBeat All Access SubscriptionMarketRank™Upgrade to All Access to use the All Ranks Filter Media sentiment refers to the percentage of positive news stories versus negative news stories a company has received in the past week.Available with a MarketBeat All Access SubscriptionMedia SentimentUpgrade to All Access to use the All Sentiments Filter Analyst consensus is the average investment recommendation among Wall Street research analysts.Available with a MarketBeat All Access SubscriptionAnalyst ConsensusUpgrade to All Access to use the All Ratings Filter Reporting Date Full History Latest Per Company Show All Ratings Strong Buy Buy Hold Sell Rating All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Price Target Change Action Any Change Raised 5%+ Raised 10%+ Raised 20%+ Lowered 5%+ Lowered 10%+ Lowered 20%+ Price Target Change Export CompanyCurrent PriceReport DateAnalystActionPrice TargetRating12-Month Recommendation ROIDetailsBKHYYBank Hapoalim$129.45-2.4%1/22/2021 UpgradeNeutral ➝ Buy00.00%View details for Hapoalim Securities rating of Bank Hapoalim (OTCMKTS:BKHYY) on 1/22/2021PLXProtalix BioTherapeutics$1.98-1.0%5/6/2011 UpgradeSell ➝ Hold00.00%View details for Hapoalim Securities rating of Protalix BioTherapeutics (NYSE:PLX) on 5/6/2011FSLRFirst Solar$233.37+0.8%4/27/2011 Reiterated Rating$120.00Sell00.00%View details for Hapoalim Securities rating of First Solar (NASDAQ:FSLR) on 4/27/2011AMRNAmarin$14.56-1.5%4/19/2011 Boost Price Target$240.00 ➝ $460.0000.00%View details for Hapoalim Securities rating of Amarin (NASDAQ:AMRN) on 4/19/2011LLYEli Lilly and Company$1,005.20-0.1%4/19/2011 Upgrade$39.00Hold ➝ Buy00.00%View details for Hapoalim Securities rating of Eli Lilly and Company (NYSE:LLY) on 4/19/2011VNDAVanda Pharmaceuticals$6.28-1.7%4/12/2011 Reiterated Rating$15.00Buy00.00%View details for Hapoalim Securities rating of Vanda Pharmaceuticals (NASDAQ:VNDA) on 4/12/2011MNKDMannKind$3.09-4.0%4/11/2011 Reiterated RatingSell00.00%View details for Hapoalim Securities rating of MannKind (NASDAQ:MNKD) on 4/11/2011AMRNAmarin$14.56-1.5%3/31/2011 Reiterated Rating$240.00Buy00.00%View details for Hapoalim Securities rating of Amarin (NASDAQ:AMRN) on 3/31/2011CBIOCrescent Biopharma$19.97-5.9%3/25/2011 UpgradeBuy00.00%View details for Hapoalim Securities rating of Crescent Biopharma (NASDAQ:CBIO) on 3/25/2011NKTRNektar Therapeutics$70.62-5.0%3/2/2011 Lower Price Target$285.00 ➝ $255.0000.00%View details for Hapoalim Securities rating of Nektar Therapeutics (NASDAQ:NKTR) on 3/2/2011FSLRFirst Solar$233.37+0.8%2/25/2011 Boost Price Target$125.00Sell00.00%View details for Hapoalim Securities rating of First Solar (NASDAQ:FSLR) on 2/25/2011LLYEli Lilly and Company$1,005.20-0.1%1/12/2011 Upgrade$30.00 ➝ $33.00Sell ➝ Hold00.00%View details for Hapoalim Securities rating of Eli Lilly and Company (NYSE:LLY) on 1/12/2011 MarketBeat Community Rating for Hapoalim SecuritiesMarketBeat's community ratings are surveys of what our community members think about Hapoalim Securities and other research firms in the last 90 days. Vote "Outperform" if you believe Hapoalim Securities's recommendations will outperform the broader market over the long term. Vote "Underperform" if you believe Hapoalim Securities's recommendations will underperform the broader market over the long term. You may vote once every thirty days. Log in to vote on this brokerage. COMMUNITY RATINGS2.6out of 5 (last 90 days)2.6 of 5 stars OUTPERFORM VOTES 34 Believe will outperform the market UNDERPERFORM VOTES 31 Believe will underperform the market Best & Worst CallsBest Call000.0%OTCMKTS:BKHYYUpgrade • Jan 22, 2021Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%OTCMKTS:STRIInitiated Coverage • Dec 22, 2010Subscribe to MarketBeat All Access to get analyst recommendation ROI. Hapoalim Securities - Frequently Asked Questions What is the difference between Hapoalim Securities' buy, hold, and sell ratings? A buy rating indicates the analyst expects the stock to outperform the market over the next 12 months. A hold suggests the stock will perform in line with the market. A sell rating indicates expected underperformance. Hapoalim Securities uses Outperform, Market Perform, and Underperform as their equivalents. Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenWeiss RatingsUBS GroupCitigroupBarclaysWells Fargo & CompanyMorgan StanleyRoyal Bank Of CanadaJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerStifel Nicolaus Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
